Seen And Heard: Congressional Investigator Slams FDA Office Of Chief Counsel On Heparin Case
This article was originally published in PharmAsia News
Executive Summary
A senior investigator for the House Energy and Commerce Committee testified at an April 29 hearing that FDA's Office of Chief Counsel had thwarted a congressional investigation into heparin contamination in China. David Nelson said the OCC refused to provide documents relating to FDA's inspection process and would not let investigators interview OCC staff attorneys